Compare Funko Inc (FNKO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Recursion Pharmaceuticals Inc — how do they compare? Funko Inc trades at $6.47 (market cap $363.97M), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 5.9× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| FNKO | RXRX | |
|---|---|---|
Market Cap | $363.97M | $2.14B |
Volume | 1,422,651 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $6.79 |
52-Week Low | $2.81 | $2.84 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $584.62M | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $6.525, up 3.41% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue declined to $908.21M in 2025, but Q2 2026 results showed 7% sales growth and improved EBITDA margins. The company maintains a low P/S ratio of 0.38 and reduced debt, while analyst consensus is a 'Hold' with a $7.58 price target.
The outlook is cautiously optimistic; valuation appears attractive, but negative net income and volatile cash flows pose risks. Upside depends on sustained EBITDA growth and execution of the 'Make Culture POP' strategy, while competitive pressures and consumer spending trends remain key watchpoints for investors.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
